Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules
|
|
- Garey Shields
- 2 years ago
- Views:
Transcription
1 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) June 2015 Pharmaceutical Quality/CMC
2 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD Phone: or ; Fax: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) June 2015 Pharmaceutical Quality/CMC
3 TABLE OF CONTENTS I. INTRODUCTION... 1 II. BACKGROUND... 2 A. Differences in Size and Shape of Tablets and Capsules between a Reference Listed Drug and a Drug Product Subject to an Abbreviated New Drug Application Size Shape Patient Factors... 4 B. Other Physical Attribute Considerations... 4 III. RECOMMENDATIONS... 4 A. Size... 4 B. Shape... 5 C. Other Physical Attributes... 6 D. Biowaivers... 6
4 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules Guidance for Industry 1 This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not create any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. I. INTRODUCTION Tablets and capsules are widely manufactured and prescribed and may provide a number of advantages over other dosage forms, including ease of storage, portability, ease of administration, and accuracy in dosing. While generic formulations of these drug products are required to be both pharmaceutically and therapeutically equivalent to a reference listed drug (RLD), 2 we are concerned that differences in physical characteristics (e.g., size and shape of the tablet or capsule) may affect patient compliance and acceptability of medication regimens or could lead to medication errors. We believe these patient safety concerns are important, and we are recommending that generic drug manufacturers consider physical attributes when they develop quality target product profiles (QTPPs) for their generic product candidates. The recommendations in this guidance apply to abbreviated new drug applications (ANDAs) and their supplements for additional strengths that are submitted to the Office of Generic Drugs (OGD). This guidance does not apply to approved ANDAs (generic drugs) already on the market. 3 However, if the Agency determines that an approved product should be modified because the size or shape of a product poses a risk to public health, we will notify the holder of the ANDA. 1 This guidance has been prepared by the Office of Generic Drugs and the Office of Pharmaceutical Quality in the Center for Drug Evaluation and Research. 2 Reference listed drug means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. See 21 CFR 314.3(b). FDA publishes the identification of RLDs in the Approved Drug Products with Therapeutic Equivalence Evaluations (i.e., Orange Book). 3 If the manufacturer of a RLD makes a postapproval change to the size or shape of a previously approved tablet or capsule, the generic versions generally will not need to be modified. However, the Agency could ask for modifications to the product if there are safety concerns because of the differences in physical characteristics. 1
5 This guidance is not intended to apply to other oral dosage forms (e.g., chewable tablets, oral tablets for suspension/solution, orally disintegrating tablets, sublingual tablets, troches, gums). In general, FDA s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. BACKGROUND A. Differences in Size and Shape of Tablets and Capsules between a Reference Listed Drug and a Drug Product Subject to an Abbreviated New Drug Application 1. Size Difficulty swallowing tablets and capsules can be a problem for many individuals and can lead to a variety of adverse events and patient noncompliance with treatment regimens. It is estimated that over 16 million people in the United States have some difficulty swallowing, also known as dysphagia. 4,5 For these individuals, swallowing a tablet or a capsule can be particularly challenging. A survey of adults on difficulties swallowing tablets and capsules suggests that this problem goes well beyond the patient population with clinically recognized dysphagia and may affect as many as 40 percent of Americans. Of those who experience difficulty swallowing medications, less than a quarter discuss the problem with a health care professional, 8 percent admit to skipping a dose of prescribed medication, and 4 percent have discontinued therapy because the tablets and/or capsules were difficult to swallow. 6 Individuals who find it difficult to swallow tablets and capsules frequently cite the size as the main reason for the difficulty in swallowing. 7,8 Size and shape of tablets and capsules affect the transit of the product through the pharynx and esophagus and may directly affect a patient s ability to swallow a particular drug product. Larger tablets and capsules have been shown to have a prolonged esophageal transit time. This can lead to disintegration of the product in the esophagus and/or cause injury to the esophagus, resulting in pain and localized esophagitis and the potential for serious sequelae including 4 Agency for Health Care Policy and Research, March 1999, Diagnosis and Treatment of Swallowing Disorders (Dysphagia) in Acute-Care Stroke Patients. Summary, Evidence Report/Technology Assessment: Number 8. 5 Robbins J et al., August 21, 2001, July/August 2002, Dysphagia Research in the 21st Century and Beyond: Proceedings From Dysphagia Experts Meeting, Journal of Rehabilitation Research and Development, 39 No. 4, Harris Interactive Inc. for Schwarz Pharma, 2003, Pill-Swallowing Problems in America: A National Survey of Adults See footnote 4. 8 Bhosle M, Benner J, DeKoven M, Shelton J., 2009, Difficult to Swallow: Patient Preferences for Alternative Valproate Pharmaceutical Formulations. Patient Prefer Adherence 3,
6 ulceration, stricture, and perforation. 9,10 Other adverse events such as pain, gagging, choking, and aspiration are related to swallowing difficulties in the oropharyngeal phase of swallowing and increasingly occur at larger tablet and capsule sizes. 11,12 Studies in adults evaluating the effect of tablet and capsule size on ease of swallowing suggest that increases in size are associated with increases in patient complaints related to swallowing difficulties at tablet sizes greater than approximately 8 mm in diameter. 13,14,15 The size of the tablet or capsule influences esophageal transit, irrespective of patient factors and administration techniques (i.e., use of fluids, patient position). Smaller tablets generally have been shown to have significantly faster transit times in these studies. Channer and Virjee specifically compared the transit time of 8 mm diameter round tablets to 11 mm diameter round tablets and 14 mm x 9 mm oval tablets and found the transit times for the 8 mm round tablet to be significantly shorter than for 11 mm round and 14 mm x 9 mm oval tablets (p<.02 and p<.04, respectively). 16 In addition, significantly more patients were aware of the larger round tablets (>8 mm) sticking in the esophagus compared with the 8 mm round tablets. 17 Although there has been less research quantifying the effects of size difference on the oropharyngeal phase of swallowing, increasing tablet or capsule size is believed to correlate with increasing difficulty with oropharyngeal transfer. 2. Shape For any given size, certain shapes may be easier to swallow than others. In vitro studies suggest that flat tablets have greater adherence to the esophagus than capsule-shaped tablets. 18 Studies in humans have also suggested that oval tablets may be easier to swallow and have faster esophageal transit times than round tablets of the same weight. 19,20 Patient compliance with medication regimens may be influenced by the size and shape of a tablet or capsule. 9 Drug and Therapeutics Bulletin, 1981; Tablets and Capsules that Stick in the Oesophagus, 19(9), Channer, K, Virjee, JP. 1986, The Effect of Size and Shape of Tablets on their Esophageal Transit. Journal of Clinical Pharmacology, 26, Kelly J, D Cruz G, Wright D, 2010, Patients with Dysphagia: Experiences of Taking Medication. Journal of Advanced Nursing 66(1), Jackson LD, Little J, Kung E, Williams EM, Siemiatkowska K, Plowman S, 2008, Safe Medication Swallowing in Dysphagia; A Collaborative improvement Project. Healthcare Quarterly 11, See footnote Wamberg T., Jorgensen, F., Hasselbalch, H., Hey, H., 1983, The Prejudgement of the Esophageal Transfer of Tablets and Capsules. Archiv der Pharmazie Chemistry in Life Sciences, Ed. 11, Brotherman, DP,. Bayraktaroglu, T.O., Garofalo, R.J., 2004, Comparison of Ease of Swallowing of Dietary Supplement Products for Age-Related Eye Disease. Journal of American Pharmacists Association, 44, See footnote Ibid. 18 Marvola M., Rajaniemi M., Marttila E., Vahervuo K., Sothmann A., 1983, Effect of Dosage Form and Formulation Factors on the Adherence of Drugs to the Esophagus. Journal of Pharmaceutical Sciences 72(9), See footnote Hey H., Jorgensen F., Sorensen K., Hasselbelch H., Wamberg T., 1982, Esophageal Transit of Six Commonly used Tablets and Capsules. British Medical Journal 285,
7 Patient Factors The Agency recognizes that a variety of other factors may affect a patient s ability to swallow a tablet or a capsule. For example, age could be a factor. Children and adolescents, as well as the elderly, are more likely to have difficulty swallowing tablets or capsules. Body position, fluid intake, and the presence of certain medical conditions (e.g., multiple sclerosis, muscular dystrophy, Parkinson's disease) may also affect a patient s ability to swallow tablets and capsules. Although not all patient factors can be addressed through pharmaceutical design and manufacture, the physical characteristics of a product can be addressed. These physical characteristics influence the ability of certain patients to swallow the product, particularly in vulnerable populations. We believe that tablets and capsules can be effectively developed and manufactured to minimize swallowing difficulties, which can encourage and improve patient compliance with medication regimens. FDA recommends that applicants design and develop generic drugs with this in mind. B. Other Physical Attribute Considerations The presence and composition of a coating can also potentially affect the ease of swallowing tablets or capsules. The lack of a film coating can decrease or prevent tablet mobility compared with a coated tablet of the same size and shape. Coating also can affect other factors that contribute to patient acceptance, such as palatability and smell. The weight of the tablet or capsule also may affect transit time, with heavier tablets or capsules having faster transit times compared to similarly-sized, lighter tablets or capsules. Surface area, disintegration time, and propensity for swelling when swallowed are additional parameters that can influence esophageal transit time and have the potential to affect the performance of the drug product for its intended use. These physical attributes should also be considered when developing a QTPP for generic drug products intended to be swallowed intact. III. RECOMMENDATIONS The recommendations in this guidance are based on published literature regarding patient experiences swallowing tablets and capsules and Agency experience with NDAs and ANDAs submitted for oral tablets and capsules. If a tablet or capsule intended to be swallowed intact differs from the criteria recommended in this guidance document, then the applicant should contact OGD with supportive information and justification before establishing the QTPP. A. Size For comparable ease of swallowing as well as patient acceptance and compliance with treatment regimens, the Agency recommends that generic oral tablets and capsules intended to be swallowed intact should be of a similar size to the corresponding RLD. The Agency recommends limiting size differences between therapeutically equivalent tablets as follows: 4
8 If the RLD is less than 17 mm in its largest dimension, 21 the generic product should be: o No more than 20 percent larger than the RLD in any single dimension (the resulting single dimension of the generic should not exceed 17 mm). o No more than 40 percent larger than the volume of the RLD. 22 If the RLD is equal to or greater than 17 mm in its largest dimension, the generic product should be: o No larger than the RLD in any single dimension. o No larger than the volume of the RLD. We recommend that the largest dimension of a tablet or capsule should not exceed 22 mm and that capsules should not exceed a standard 00 size. 23 Additional flexibility may be given for products that are 8 mm or smaller in their largest dimension, but efforts should be made to develop tablets and capsules that are of a similar size and shape to the RLD. Under the standard capsule size convention, the allowances described above will generally allow an increase of one capsule size, when the RLD capsule is of size 3 or smaller. When the RLD capsule is of size 2 or larger, an increase of one capsule size should only be considered when adequate justification can be provided for the size increase. These recommendations would allow an increase of one capsule size when the capsule size is less than capsule size 00. The Agency recognizes that two drug products may have different recommended upper size limits, but size should be considered as part of a single product risk/benefit profile. When establishing therapeutic equivalence, the applicant should compare their generic product only to the RLD. B. Shape In addition to the size recommendations described above, we recommend manufacturing tablets and capsules that have a similar shape or have a shape that has been found to be easier to swallow compared with the shape of the RLD. Evaluating and comparing the largest cross sectional areas of the RLD and generic product is one strategy to quantify changes in shape. 24 Tablets and capsules that have a larger cross sectional area (e.g., tablets that are rounder) would generally be more difficult to swallow than tablets or capsules of the same volume but with smaller cross sectional areas. 21 The largest dimension refers to the length of oval or capsule shaped tablets or the diameter of round tablets. 22 For the purposes of this guidance, volume refers to the volume occupied by the tablet or capsule. 23 An internationally accepted numbering system for capsule sizes is used in approved U.S. drug products. For the purpose of this guidance, a liquid fill capsule is considered a capsule. 24 For the purposes of this guidance, the largest cross sectional area is defined by the largest cross sectional area of the tablet that lies in a plane perpendicular to the longest axis of the tablet. If the shape of tablet is unconventional (e.g., pentagon, triangle, diamond, heart), then the largest cross sectional area will be defined as the area of the smallest circle, oval, or ellipse that would completely enclose this largest cross sectional shape. 5
9 There are a variety of techniques that may be used to determine the volume measurements of a tablet or capsule, including use of pycnometers, or calculations based on physical measurements of the tablet or the die used to produce the tablet. For the purpose of this guidance, spatial imaging and/or the use of computer models is recommended, because they are more accurate and applicable to a variety of shapes, although other appropriately validated methods may be used if properly justified. The size of a tablet or capsule should be provided in the common technical document (CTD) format, 25 section 3.2.P.1, Description and Composition of the Drug Product of the ANDA. Any studies and/or related information should be provided in the CTD section, , Comparative Bioavailability and Bioequivalence Study Reports. The Agency may request samples for evaluation of the physical attributes of a tablet or capsule. C. Other Physical Attributes Other physical attributes of tablets and capsules should be considered in the context of their effect on ease of swallowing. For example, tablet coating, weight, surface area, disintegration time, and propensity for swelling should be considered when developing a QTPP for generic tablets. Description of these physical characteristics should be provided in the CTD section 3.2.P.1, Description and Composition of the Drug Product of the ANDA. A summary of any studies to support sizes outside the recommendation provided in this guidance should be provided in the CTD section 3.2.P.2, Pharmaceutical Development or CTD section 3.2.P.5.6, Justification of Specifications. D. Biowaivers A biowaiver (i.e., the waiver of in vivo bioequivalence data) for additional strengths of a solid oral dosage form is generally granted if it meets one of the criteria set forth in the regulations, 26 one of which is proportional similarity between strengths in active and inactive ingredients. Compositional proportionality may be particularly relevant when considering tablet size and tablet formulation for other strengths (both lower and higher) of the same dosage form to be considered for a waiver of the in vivo bioequivalence study requirement. Although compositional proportionality may exist when all active and inactive ingredients are in the same proportion between different strengths, other methods of achieving compositional proportionality may be more amenable to maintaining appropriate tablet sizes for generic products when compared with the RLD. A detailed description of how the Agency defines proportional similarity can be found in the Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations See ICH guidance for industry M4Q: The CTD Quality. It is available on the Internet at under International Conference on Harmonisation Quality. 26 See 21 CFR (d). 27 This guidance is available on the Internet at under Biopharmaceutics. 6
10 FDA recommends that applicants consider Agency published guidance, product specific guidance, 28 and relevant regulations 29 on the waiver process when designing and formulating other strengths of the same dosage form that will be studied with bioequivalence studies. For specific questions related to biowaivers, you should contact the appropriate review division within OGD. 28 This guidance is available on the Internet at under Bioequivalence Recommendations for Specific Products. 29 See 21 CFR
Guidance for Industry
Guidance for Industry Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Guidance for Industry
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Guidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
Guidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions
Recommended Warning for Overthe-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions Guidance for Industry DRAFT GUIDANCE This guidance document is being
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
Guidance for Industry
Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Post-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
Guidance for Industry
Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Guidance for Industry
Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the
Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,
Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for
Bioequivalence and Drug Product Quality
Bioequivalence and Drug Product Quality Vinod P. Shah, Ph. D. FIP/SIG Chair, Regulatory Sciences Pharmaceutical Consultant (Formerly with US FDA) 2 nd MENA Conference on Bioequivalence, Biowaivers, Bioanalysis,
CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Bioequivalence Requirement
Bioequivalence Waivers (Biowaivers) Ian S. Hendricks D.V.M., M.Ed., Ph.D. Division of Generic Animal Drugs AAVPT Veterinary Drug Regulatory Life Cycle Course Bioequivalence Requirement Any person submitting
May 18, 2011 Beijing, China. SHAO Jun, Ph.D.
Development & The US FDA Approval of Generic Drugs May 18, 2011 Beijing, China SHAO Jun, Ph.D. Agenda About Generic Drugs Business Strategy for Generic Drugs Generic Drug Product Development Generic Drug
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs
Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs Integration Communication Collaboration John R Peters, MD Director, Division of Clinical Review Office of Generic Drugs 1
Guidance for Industry
Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
Opinions expressed in this presentation are those of the speaker and do not necessarily reflect the views or policies of the FDA
Opinions expressed in this presentation are those of the speaker and do not necessarily reflect the views or policies of the FDA Generic Drugs Application and Regulatory Review Naiqi Ya, Ph.D. Deputy Director
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Guidance for Industry
Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations U.S. Department of Health and Human Services Food and Drug Administration Center
Good Review Practice. October 2009 Labeling
Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good
The 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
Inactive Ingredient Database - FDA Update -
Inactive Ingredient Database - FDA Update - Naiqi Ya, Ph.D. Acting Director for Chemistry Division IV Office of Generic Drugs Food and Drug Administration The USP Excipients Stakeholder Forum June 18,2014
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
The Role of Orange Book in Bioequivalence. Aaron W. Sigler, Pharm.D., BCPS Office of Generic Drugs Division of Bioequivalence II
The Role of Orange Book in Bioequivalence Aaron W. Sigler, Pharm.D., BCPS Office of Generic Drugs Division of Bioequivalence II 1 The following presentation reflects the opinions of the author and does
Guidance for Industry DRAFT GUIDANCE
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
Use of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Opadry II / Opadry / Opaglos 2
Opadry II / Opadry / Opaglos 2 Application Data High Productivity Film Coating / Complete Film Coating System / High Gloss Film Coating Systems Modern Tablet Film Coatings and Influence on Ease of Swallowing
ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING
ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING For More Information on Submission of an ANDA in Electronic Common Technical Document (ectd) Format
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
DEPARTMENT OF HEALTH & HUMAN SERVICES NDA 17-854 NDA 21-793 NDA 17-862. [inside address] Dear :
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 NDA 17-854 [inside address] Dear : Please refer to your new drug application NDA xx-xxx for
ICH Topic Q4B Annex 5 Disintegration Test General Chapter. Step 3
European Medicines Agency June 2008 EMEA/CHMP/ICH/308895/2008 ICH Topic Q4B Annex 5 Disintegration Test General Chapter Step 3 ANNEX 5 TO NOTE FOR EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS
GDUFA Regulatory Science Update
GDUFA Regulatory Science Update Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA GPhA Annual Meeting Feb 9, 2015 Goals
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidance for Industry
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data DRAFT GUIDANCE This guidance document is being
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010
GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Disclaimer & Disclosure Views presented are those of the
Guidance for Industry
Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance
Bioequivalence Data Submission Requirements
Bioequivalence Data Submission Requirements Hanan Kakish Medical Research Scientist, M.Sc. Pharm. Middle East and North Africa Post U.S. Food and Drug Administration Amman, Jordan Hanan.kakish@fda.hhs.gov
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
Food and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
Generic Drug User Fee Act Program Performance Goals and Procedures
Generic Drug User Fee Act Program Performance Goals and Procedures The performance efficiencies, metric goals and procedures to which FDA will agree upon commencement of a generic drug user fee act (GDUFA)
NUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
BIOAVAILABILITY AND BIOEQIVALENCE
UNIT 5 BIOAVAILABILITY AND BIOEQIVALENCE S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University BIOAVAILABILITY INTRODUCTION The bioavailability or systemic
Guidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
GUIDANCE ON PROCESS VALIDATION SCHEME FOR SOLID ORAL DOSAGE PRODUCTS TABLE OF CONTENTS 1. PURPOSE SCOPE GENERAL INFORMATION...
ANNEX A1 GUIDANCE ON PROCESS VALIDATION SCHEME FOR SOLID ORAL DOSAGE PRODUCTS TABLE OF CONTENTS 1. PURPOSE... 2 2. SCOPE... 2 3. GENERAL INFORMATION... 2 4. VALIDATION SCHEME OF SOLID ORAL DOSAGE MANUFACTURING
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Generic drugs are copies of innovator drug products
dx.doi.org/10.14227/dt190412p51 In Vitro Equivalence Studies of Generic Metformin Hydrochloride Tablets and Propranolol Hydrochloride Tablets Under Biowaiver Conditions in Lagos State, Nigeria e-mail:
Guidance for Industry
Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Pharmaceutical Manufacturing for New Drugs Current Status and Vision for the Future
Pharmaceutical Manufacturing for New Drugs Current Status and Vision for the Future NIPTE Research Conference on The Future of Pharmaceutical Manufacturing June 18, 2013 Elaine Morefield, Ph.D. Deputy
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
Guidance for Industry
Guidance for Industry Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved Antiretrovirals for the Treatment of HIV U.S. Department of Health and Human Services
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for
Factors Effecting Bioavailability Studies
Online Available at www.thepharmajournal.com THE PHARMA INNOVATION Factors Effecting Bioavailability Studies Bodavula Samba Siva Rao* Department of Pharmacy, Khammam college of pharmacy, Khammam, Andhra
Guideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
Medication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products U.S. Department of Health and Human Services Food and Drug Administration
NDA 202439/S-008 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202439/S-008 SUPPLEMENT APPROVAL Janssen Pharmaceuticals, Inc. ATTENTION: Alla Rhoge Pharm.D., Associate
Research on Tablet Splitting
On behalf of the American Society of Consultant Pharmacists (ASCP) and its Ohio members, we are writing to express our concern over a recent proposal to implement a tablet splitting initiative under the
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Pharmaceutical Science for Generic Drugs: The Science of Equivalence
Pharmaceutical Science for Generic Drugs: The Science of Equivalence Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research,
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for Industry
#171 Guidance for Industry Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles (This version of the guidance replaces
U.S. Bureau of Labor Statistics. Pharmacy Tech
From the: U.S. Bureau of Labor Statistics Pharmacy Tech Pharmacy technicians fill prescriptions and check inventory. Pharmacy technicians help licensed pharmacists dispense prescription medication. They
Bundesinstitut für Arzneimittel und Medizinprodukte. Dissolution Testing. Analytik,Methodenentwicklung, Bioäquivalenz SAQ. Olten, 25.
Dissolution Testing Analytik,Methodenentwicklung, Bioäquivalenz SAQ Olten, 25. Januar 2006 Dr. H. Potthast (h.potthast@bfarm.de) 1 2 Basis for Biowaiver Applications/Decisions Note for Guidance on the
Regulatory Expectations of Presentation of Dissolution Data
Safeguarding public health Regulatory Expectations of Presentation of Dissolution Data David Darling Pharmaceutical Assessor Medicines and Healthcare products Regulatory Agency (MHRA), UK Content Why Use
Guidance for Industry
Guidance for Industry Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
Guidance for Industry
Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
Guidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance for Industry Bar Code Label Requirements Questions and Answers
Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation
Nursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics